Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

NCT04388475 is registered in ClinicalTrials.gov with Oblato, Inc. as lead sponsor.

NCT NCT04388475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04388475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
Lead sponsor
Oblato, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 12, 2020
Completion date
March 5, 2025
Enrollment
57 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

brain glioblastoma, recurrent malignant glioma